Sanofi has agreed to spend $470 million to take control of a young biotechnology company and its experimental drug for Alzheimer’s disease. The newly announced acquisition has Sanofi paying $8 for ...

Biocon Limited witnessed a gain of over 2% in its stock price in Wednesday morning trade after its subsidiary announced that its commercial partner in Japan launched the Ustekinumab BS Subcutaneous.

Bags of Cash From Drug Cartels Flood Teller Windows at U.S. Banks Chinese money-launderers allegedly made six-figure deposits at Chase, Bank of America and Citibank branches across Los Angeles County ...

Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and more than 15 additional drugs scheduled to be launched in the remainder of 2025.

Cordis announced new data from two major peripheral studies evaluating its Selution SLR drug-eluting balloon.

Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess its impact on cardiovascular events.

U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of October 13, 2025 Application supported by positive efficacy and safety data from ...

For decades, doctors told healthy older adults to take an over-the-counter drug daily to prevent heart attack or stroke. The guidance has since changed — but many older adults are still taking it.

Report: Generic prescriptions marked up 5,000% A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, finding the companies ...

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis.

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections.

AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, widening rival Bristol Myers Squibb's lead in the market ...